0001104659-22-098035.txt : 20220907 0001104659-22-098035.hdr.sgml : 20220907 20220907070035 ACCESSION NUMBER: 0001104659-22-098035 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220901 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220907 DATE AS OF CHANGE: 20220907 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LEAP THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001509745 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274412575 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37990 FILM NUMBER: 221229893 BUSINESS ADDRESS: STREET 1: 47 THORNDIKE STREET STREET 2: SUITE B1-1 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617 252 4343 MAIL ADDRESS: STREET 1: 47 THORNDIKE STREET STREET 2: SUITE B1-1 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Dekkun Corp DATE OF NAME CHANGE: 20110107 8-K 1 tm2225135d1_8k.htm FORM 8-K
0001509745 false 0001509745 2022-09-01 2022-09-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(D)

of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): September 1, 2022

 

 

 

Leap Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37990   27-4412575
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

47 Thorndike Street, Suite B1-1
Cambridge, MA 		02141
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (617) 714-0360

 

N/A

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

 

¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

 

¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

Securities registered pursuant to Section 12(b) of the Act: 

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common Stock, par value $0.001 LPTX Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On September 1, 2022, the Board of Directors (the “Board”) of Leap Therapeutics, Inc. (the “Company”) appointed Richard Schilsky, M.D. as a Class I director of the Board. Dr. Schilsky has not been appointed to any committees of the Board at this time.

 

There are no arrangements or understandings between Dr. Schilsky and any other person pursuant to which Dr. Schilsky was appointed as a director, and Dr. Schilsky is not a party to any transaction with the Company reportable pursuant to Item 404(a) of Regulation S-K. Dr. Schilsky’s compensation will be consistent with other non-employee members of the Board, which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 28, 2022, as may be amended from time to time by the Board.

 

On September 6, 2022, the Company issued a press release announcing the appointment of Dr. Schilsky to the Board. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference; provided, however, that information on or connected to our website referenced in the Company’s press release is expressly not incorporated by reference into or intended to be filed as a part of this Current Report on Form 8-K.

 

Item 8.01.Other Events.

 

On September 4, 2022, the Company issued a press release entitled “Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress.”

 

The full text of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference; provided, however that information on or connected to our website referenced in the Company’s press release is expressly not incorporated by reference into or intended to be filed as a part of this Current Report on Form 8-K.

 

Item 9.01.Financial Statements and Exhibits.

 

(d)         Exhibits.

 

Exhibit
Number		   Description
99.1   Press release dated September 6, 2022 (Schilsky Appointment)
99.2   Press release dated September 4, 2022 (ESMO Presentation)
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

- 2 -

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  LEAP THERAPEUTICS, INC.
   
Dated: September 7, 2022 By: /s/ Douglas E. Onsi
  Name: Douglas E. Onsi
  Title: Chief Executive Officer and President

 

 

 

 EX-99.1 2 tm2225135d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

 

Cambridge, MA – September 6, 2022 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the appointment of Richard L. Schilsky, MD, FASCO, FACP, FSCT to its Board of Directors, effective September 1, 2022. Dr. Schilsky brings over 40 years of experience in medicine and clinical research, specializing in new drug development and clinical trials for a wide range of cancers.

 

“We are honored to welcome Dr. Schilsky, who brings a wealth of experience and deep knowledge to bolster Leap’s drug development strategy,” said Christopher Mirabelli, PhD, Chairman of Leap Therapeutics’ Board. “He is a recognized key opinion leader in cancer research who has served in many academic and cooperative group leadership positions and on the FDA Oncologic Drugs Advisory Committee. We look forward to leveraging his expertise to support our major clinical initiatives and regulatory strategy in the years to come.”

 

“I'm thrilled to join the Board of Leap at such an exciting time for the Company as we continue demonstrating the significant potential that DKN-01 has in treating patients with solid tumors, particularly those whose tumors express high levels of DKK1,” said Dr. Schilsky. “I look forward to collaborating with my fellow Board members and the entire Leap management and scientific team to advance the pipeline and deliver meaningful cancer therapies to patients around the world.”

 

Dr. Schilsky is the former Chief Medical Officer and Executive Vice President of the American Society of Clinical Oncology (ASCO), and served as its President from 2008-2009. He spent the majority of his career at the University of Chicago, joining the faculty in 1984, and serving in many leadership positions including as Associate Dean for Clinical Research in the Biological Sciences Division, Chief of Hematology/Oncology in the Department of Medicine, and Director of the University of Chicago Cancer Research Center. From 1995 to 2010, Dr. Schilsky served as Chair of the Cancer and Leukemia Group B (CALGB), a national cooperative clinical research group funded by the National Cancer Institute (NCI). He has extensive experience working with both the NCI and the Food and Drug Administration (FDA) having served as a member and Chair of the NCI Board of Scientific Advisors, member of the NCI Clinical and Translational Research Committee, and member and Chair of the Oncologic Drugs Advisory Committee (ODAC) of the FDA. Dr. Schilsky has served on the editorial boards of many cancer journals, including the Journal of Clinical Oncology, and presently serves on the editorial board of the New England Journal of Medicine. Dr. Schilsky received his BA from the University of Pennsylvania and MD from the University of Chicago Pritzker School of Medicine.

 

About Leap Therapeutics

 

Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Leap has entered into a strategic collaboration with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.

 

 

 

  

FORWARD-LOOKING STATEMENTS

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include expectations with respect to the development and advancement of DKN-01, board leadership prospects and strategies, and other future expectations, plans and prospects. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited to: that the initiation, conduct, and completion of clinical trials, laboratory operations, manufacturing campaigns, and other studies may be delayed, adversely affected, or impacted by COVID-19, global conflict or supply chain related issues; unstable global market and economic conditions; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially is included in Leap Therapeutics' periodic filings with the SEC, including Leap's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 11, 2022 and as may be updated by Leap's Quarterly Reports on Form 10-Q and the other reports Leap files from time to time with the SEC. Any forward-looking statement contained in this release speaks only as of its date. Leap undertakes no obligation to update any forward-looking statement contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

 

CONTACT:

 

Douglas E. Onsi

President & Chief Executive Officer

Leap Therapeutics, Inc.

617-714-0360

donsi@leaptx.com

 

Matthew DeYoung

Investor Relations

Argot Partners

212-600-1902

leap@argotpartners.com

  

 

 EX-99.2 3 tm2225135d1_ex99-2.htm EXHIBIT 99.2

 

Exhibit 99.2

 

 

 

 

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab

and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress

 

Median Progression-Free Survival of 11.3 months in first-line gastric cancer patients treated with DKN-01 plus tislelizumab and CAPOX, exceeding benchmarks in the overall population and in DKK1 and PD-L1 subgroups

 

Median Overall Survival is not mature with only 44% of patients deceased as of the data cut

 

Enrollment ongoing in the study of DKN-01 plus Tecentriq® (atezolizumab) in second- or third-line oesophagogastric cancer patients, activity in DKK1-high patients consistent with prior studies with pembrolizumab or tislelizumab

 

Cambridge, MA – September 4, 2022 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting data in first-line patients with advanced gastroesophageal adenocarcinoma (GEA) from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy, at the European Society for Medical Oncology (ESMO) Congress 2022 being held on September 9-12. Safety and early efficacy data will be presented from the WAKING study, a multicenter Phase 2 non-randomized trial evaluating DKN-01 plus Tecentriq® (atezolizumab), Roche’s anti-PD-L1 antibody, in patients with advanced oesophagogastric adenocarcinoma (OGA).

 

“Data from the DisTinGuish study continue to demonstrate promising results with the combination of DKN-01 plus tislelizumab and standard chemotherapy as a first-line treatment in patients with advanced gastroesophageal adenocarcinomas,” said Samuel Klempner, MD, Associate Professor at Harvard Medical School. “The mature median progression-free survival of 11.3 months compares favorably with recent benchmarks in this patient group. The outcomes in the aggressive DKK1-high and the less checkpoint-inhibitor sensitive PD-L1-low (CPS < 5) subgroups are notable and encouraging. As the last patient enrolled in early April 2021, the overall survival results are also on track to show an increase over current standards. Gastroesophageal cancer patients and physicians want new biomarker-directed therapies to improve the standard of care in first-line treatment, and we are enthusiastic about the upcoming randomized clinical trial involving this encouraging DKN-01 combination.”

 

“Early results from the WAKING study show the promise of boosting anti-tumor activity by targeting the Wnt signaling pathway and DKK1-driven tumor microenvironment modulation with a DKN-01 plus atezolizumab combination therapy strategy in patients with advanced OGA,” said Fiona Turkes, MD, Clinical Research Fellow at The Royal Marsden Hospital. “We look forward to continuing to enroll patients and studying the biological mechanisms of this unique chemotherapy-free combination therapy, especially in those patients whose tumors express high levels of DKK1.”

 

Key Findings DisTinGuish

 

▪DKN-01 and tislelizumab plus CAPOX was well tolerated in first-line treatment for advanced GEA patients, with a safety profile consistent with previous reports
▪Overall median progression-free-survival (PFS) of 11.3 months exceeds benchmark results in unselected patients and in all four important biomarker-directed subgroups
▪11.3 months PFS in DKK1-high and 12.0 months in DKK1-low
▪10.7 months PFS in PD-L1-low (CPS < 5) and 11.6 months in PD-L1-high (CPS > 5)
▪Median overall survival (OS) is not mature with only 44% of patients deceased as of the data cut (June 30, 2022), with a median duration on study of 15.7 months and last patient enrolled in early April 2021

 

 

 

 

▪High and durable overall response rate (ORR) in unselected and aggressive subgroups (DKK1-high and PD-L1-low) (mITT): 68% (1 CR, 14 PR) overall
▪DKK1-high: 90% ORR (9 PR)
▪DKK1-low: 56% ORR (1 CR; 4 PR)
▪PD-L1-low expression: 79% (11 PR)
▪100% (6/6) ORR in DKK1-high, PD-L1-low patients
▪PD-L1-high expression: 67% (1 CR; 3 PR)
▪75% (3/4) ORR in DKK1-high, PD-L1-high patients

 

Key Findings WAKING

 

•DKN-01 up to 600mg every 2 weeks in combination with atezolizumab was considered safe
•3 patients with the longest time on treatment received the 600mg dose level
•At time of data cut off (August 16, 2022), 18 patients were enrolled in the study
•12 patients were treated in initial phase
•10 patients were response evaluable at the time of data cut-off
•1 patient had a PR and DKK1 expression of 81% tumor percentage score (TPS)
•Disease control rate: 50% (1 PR, 4 SD, 5 PD)
•Elevated baseline DKK1 expression (TPS > 20%) may be associated with clinical response
•4 DKK1-high patients: Best ORR 25% (1 PR, 1 SD, 1 PD, 1 NE)
•Translational analyses and assessment of PD-L1 status are ongoing
•Safety
•No dose-limiting toxicity (DLT) was observed, and no formal maximum tolerated dose (MTD) was reached
•No treatment-related deaths occurred, and no dose reductions were required

 

Leap Poster Details:

 

Title: DKN-01 and Tislelizumab + Chemotherapy as First-line (1L) Investigational Therapy in Advanced Gastroesophageal Adenocarcinoma (GEA): DisTinGuish Trial

First Author: Samuel J. Klempner, Harvard Medical School

Session Category: Poster Session

Session title: Oesophagogastric cancer

Date and time: Monday, September 12, 2022, at 12:00 CET

Poster Number: 1213

 

Title: Safety and efficacy of Wnt inhibition with a DKK1 inhibitor, DKN-01, in combination with atezolizumab in patients with advanced oesophagogastric adenocarcinoma (OGA): Phase IIa results of the WAKING trial

First Author: Fiona Turkes, The Royal Marsden NHS Foundation Trust

Session Category: Poster Session

Session title: Oesophagogastric cancer

Date and time: Monday, September 12, 2022, at 12:00 CET

Poster Number: 1253

 

About the DisTinGuish Study

 

The DisTinGuish study (NCT04363801) is a Phase 2a study of DKN-01 in combination with tislelizumab, an anti-PD-1 antibody, with or without chemotherapy as first-line or second-line therapy in patients with inoperable, locally advanced, G/GEJ adenocarcinoma. The study is being conducted in two parts in the United States and the Republic of Korea. Enrollment of Part A has been completed with 25 first-line HER2- G/GEJ cancer patients whose tumors express either high levels of DKK1 (DKK1-high) or low levels of DKK1 (DKK1-low). Part B of the study has completed enrollment patients with second-line DKK1-high G/GEJ cancer. Part C of the study will be a randomized controlled trial of DKN-01 in combination with tislelizumab and chemotherapy compared to tislelizumab and chemotherapy. Leap is conducting this combination study as part of an exclusive option and license agreement with BeiGene.

 

 

 

 

About the WAKING Study

 

The WAKING study (NCT04166721) is a Phase IIa/b nonrandomized, open-label, multicenter study to be conducted concurrently in 2 Parts. Approximately 52 patients aged 18 years or older with inoperable, histologically confirmed locally advanced or metastatic G/GEJ adenocarcinoma with measurable disease (RECIST v1.1) requiring therapy will be enrolled in the study. Both parts are designed to evaluate safety, tolerability, and efficacy of the combination therapy of DKN-01 and atezolizumab in immunotherapy naïve, PD-L1 unselected G/GEJ adenocarcinoma patients. Treatment continues in repeating 14-day cycles until patient meets criteria for discontinuation or is no longer deriving clinical benefit. The WAKING study is being led by the Royal Marsden Hospital in the United Kingdom with financial support from Roche.

 

About Leap Therapeutics

 

Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Leap has entered into a strategic collaboration with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.

 

FORWARD-LOOKING STATEMENTS

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include Leap's expectations with respect to the development and advancement of DKN-01, including the initiation, timing and design of future studies, enrollment in clinical studies, potential for the receipt of future option exercise, milestone, or royalty payments from BeiGene, and other future expectations, plans and prospects. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited to: that the initiation, conduct, and completion of clinical trials, laboratory operations, manufacturing campaigns, and other studies may be delayed, adversely affected, or impacted by COVID-19, global conflict or supply chain related issues; unstable global market and economic conditions; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially is included in Leap Therapeutics' periodic filings with the SEC, including Leap's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 11, 2022 and as may be updated by Leap's Quarterly Reports on Form 10-Q and the other reports Leap files from time to time with the SEC. Any forward-looking statement contained in this release speaks only as of its date. Leap undertakes no obligation to update any forward-looking statement contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

 

CONTACT:

 

Douglas E. Onsi

President & Chief Executive Officer

Leap Therapeutics, Inc.

617-714-0360

donsi@leaptx.com

 

Matthew DeYoung

Investor Relations

Argot Partners

212-600-1902

leap@argotpartners.com

 

 

 

 EX-101.SCH 4 lptx-20220901.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 lptx-20220901_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 lptx-20220901_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2225135d1_ex99-2img001.jpg GRAPHIC begin 644 tm2225135d1_ex99-2img001.jpg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end GRAPHIC 8 tm2225135d1_ex99-1img001.jpg GRAPHIC begin 644 tm2225135d1_ex99-1img001.jpg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htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Sep. 01, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 01, 2022
Entity File Number 001-37990
Entity Registrant Name Leap Therapeutics, Inc.
Entity Central Index Key 0001509745
Entity Tax Identification Number 27-4412575
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 47 Thorndike Street
Entity Address, Address Line Two Suite B1-1
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02141
City Area Code 617
Local Phone Number 714-0360
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol LPTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 10 tm2225135d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001509745 2022-09-01 2022-09-01 iso4217:USD shares iso4217:USD shares 0001509745 false 8-K 2022-09-01 Leap Therapeutics, Inc. DE 001-37990 27-4412575 47 Thorndike Street Suite B1-1 Cambridge MA 02141 617 714-0360 false false false false Common Stock, par value $0.001 LPTX NASDAQ true false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://leaptx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2225135d1_8k.htm lptx-20220901.xsd lptx-20220901_lab.xml lptx-20220901_pre.xml tm2225135d1_ex99-1.htm tm2225135d1_ex99-2.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2225135d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2225135d1_8k.htm" ] }, "labelLink": { "local": [ "lptx-20220901_lab.xml" ] }, "presentationLink": { "local": [ "lptx-20220901_pre.xml" ] }, "schema": { "local": [ "lptx-20220901.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lptx", "nsuri": "http://leaptx.com/20220901", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2225135d1_8k.htm", "contextRef": "From2022-09-01to2022-09-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://leaptx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2225135d1_8k.htm", "contextRef": "From2022-09-01to2022-09-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://leaptx.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 17 0001104659-22-098035-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-098035-xbrl.zip M4$L#!!0 ( !$X)U7Q1:8N-@, .\+ 1 ;'!T>"TR,#(R,#DP,2YX M0B@K>=OR*YR#@@0@I'[6=JSX^Z9]V M.@XZ/GKU$IE?ZS7&Z)P""YOH3 2XPX?B$'TA$VBB3\!!$BWD(;HF++86<4X9 M2'0J)A$##<:1G=1$]8I?#Q#&6^A> P^%O.IU9KICK2/5=-WI=%KAXH%,A;Q3 ME4!,MA/L:Z)C-5/S$B__;4>_H"J8D0_(27WZ+NG1FQ'P]W&7U&Z#[P0N^H/+ M\/=M[^#RQUVB)Q\.!@-V_^OQH_9"&)B_A(Q5]?LR)8*QC AR!2#J[9C M\\O3F]8J0H[X! M43!3-EZZ 4^YTH0'3_"AGA$6P74WD<.SYN.87%"7U*MP8RZ%8/T:@2@F9JX3&(IW, M& R(V=HNME8/#-1(WLPHQ6F;)UN:?"/ X.HF'; MR996PRBF*B$,*:?I4?D$^0C;>8EM4F:94EKN,GA!(E807O*C=!U)4(:7QMXU MAIR80]:0 L*"F.W&F8=22LD-Q1W-;ZV8DAX,43I=35OYMJ.H?=^7;R \N)(@,5E16IM^(B BDIJ8]%T8\"YUJ M2_^Z< RRYR@'N?\B948&NZ9L*,#^8ZY=J[^89#X>[GP^\OWR#+5,ND)JQ%=& M<=/;F+WJ71&D4ALH=H<+'K8F[%?-0U))5#B/=)<@YC>P6Q %;X\@UK[091&H M]02[Q-ERVZ,WOO8;CR]ENL"T*BQXKK5/.*O?AF?$DXKM$="38H=:NE;(2GM6 MI[HAJ+\QT[W:JT4"$7,M'],,MVR214JQ2:]CY\HL?^>W*TK!R@IB/_W/:([R M_QSV#61]:[3<3-,L_P!02P,$% @ $3@G59.*F$+_"@ ;(< !4 !L M<'1X+3(P,C(P.3 Q7VQA8BYX;6S-G5]3Z[@9QN\[T^^@36_:F1-"H-L9V,/N M<')@)[,LL(1SMNU.9T>Q1?#@2*SL0/+M*]F68TMZ;4.GDKB 8#VO_,CZ19+_ M2/[XPW:=HA?"LX31L]'TX'"$"(U8G-#5V>C+8GR^F,WG(Y3EF,8X9924Y$0DE#L^1=\>3+^-T'@\(-^OA,:,?[F;U_D^YOES=CJ9O+Z^ M'E#V@E\9?\H.(K8>EN$BQ_DFJW,[W!Y6/V7XQS2A3Z?RUQ)G!(GC1;/3;9:< MC>1^J]V^'A\POIH<'1Y.)__\^6H1/9(U'B=4'K>(C%24S,46-STY.9D4J4IJ M*+=+GJI]'$^4G3IGD9ITZ!M.LN0T*^Q=L0CG1;7W[@:!"OG?6,G&C0^ MGAYLLWBD#GYQ!#E+R1UY0$4Q3_/=LT I2R0)HVK;(RDG2$I%+P 9;KI)57%31Q;?:6\(3%%_1]KO5H3_;% M=X?G_T,!FO'.BW#/D&Y'_%]NY:?G- MA]=^7%.Y\4I\:EDDVUQT8"16)F46'2UPL8>B8ZCRKG-G42O?5+;FC)MEESUC MD6=&HH,5>YG$)!%Y'TW_^+O\."X_%D47__X^8V(T<+[,[I.1^GY:$LPQ\X6UMW6Y6<61)_3Y=U?'EHQ"X MHRT9)QG;\(B\J6::;J&C5#E:IT(AAU6$CK\L1M\7&O2;4OWGXV2?BZ/*%D.A MS9K0_%[D:BE%.]E55=M,J9INI@51T19#>CTK"9(:#Y5\+G8>2P.7*5Y9BJ"E MNZIFJRU5SZW$("K:YDBOZ5J#I,AG57\F6<239SF\[RI+2^:\XBTFC?IO:,+" MP#0&T]#0>FSD[\@JD5V-M"'/>8G(0[#G: :A M.LHC2^>4;G!Z1YX9[T*H+7--CLVD#DQ3$Q0G%F,@'J46E6*/5/RR$6?SA*>[ M7C ,I6LV *LZ'IHL*$+LWD!(:KE_3NXYIEDB&[->4$RI\],0P*QQ2J+I@F(% M, >?JM1Z_[0L'DF:RGL&F/8W+#:Q:V)@PSHSIC(H:D![(#=%!*I"PD+GXD6. MVL70:6"!&WJ? !FVNQBJQ<%BI#L<2%(1AF2<1YH:MRQZ.#*4K@D"K.KL:+*@ MJ+%[ WDIY:C0AP'*!8T'85+K_$"BV;0C4HD"!*3MK \/H?8-QV6213@M_5R* M;5E'$2U:UY" =G50#&%0L$#N0&#* ,5-$>(=FG\1S(EE@4( MB^ZM#Q6I]P;*;,-YRSG<^\!29S=S>\S6]W4!71"P])@S[O:6\A8L'GNC"YHG M^4X^CW>]62\)MQ30E+CB S*GN-#3@^ !,*5S4,J0U*%2Z*WVU5T%FLL'(<$B MZ3*W%-A-MDEH:P*BP6H,(&*O+9Y+]4;%3+12'*=S&I/M3V0'ELW0N>4"L-D& M0Q,%1(;=&8!&)4:%&@FY-SAN>;+&?+=(HIYNPQ2ZQ0,RVN9#5P4$"& -(*12 MH\5\YKM7N2R 31Z2\OGR'E) O5M@>FRWN0'$ >'3[1"@2 2A=I1OF.8T M8OR9-1Z7F+&-: QW,Q;#(Y:>*+=@#2I"&Z_.D( @&^(30*T5^J%\I@4Q.3>H MR #)'+Q1=Q['XF!EU9^KA)(I> RL6K>$==AM[4]\ TJO6!C6K5"LY>%AXSAK0\8&2#'-S+$-RK%8.N&WW+V MDM ('D9#$+$:MH+24H:'B\U>'S1E#!)!ODZZ M*VSE#1#K=#4MW=V48XNM_93C1F(0(-@M641 $=#G3::BTJ"WV@,:"I4F4Y E=_2Q.3GF" M;26SB5Q! 1M41)B*(' ;>DL[(5(*3V <,N)A)&(RB@F',I%COC-PX.U]^\2 MNP*CW[ "!%8& 4JO/1T8$3".&A&H#$%%C']TYEFV(?Q- %E"/&$$F@=@,O0A M(@69[ 6K#/3-UX)$&]%?[J9'R_LD3VTGGJ;$6?\$F*M[)RT]"#X 4SH/11IB M#VAZ]-?EWY"*\H# -;OG6"YJN]BMERP%5L*RJER!T&%1L6"1!($#[$LGXIJA M2HI*K:^5LEJ&+472TEU!8+6EJK^5&$3%VQP9C4"KOCTV_Q?;Z%$8(\!D![O, M=3=@,ZEW!4U-$!AT&#-.5BHI4EI?DQWV7=BJ?U"P\C8H6/4,"E8A#@I60P<% M*Z^# K7K7^(,V(&FJ_AZ=&'P=$PDP9299A:8[$.W"_#Z>.R M>_D0QZ\D37^B[)4N",X8)7%YO<5V=ZE;[_:IFQ[;[0=O '$02 UQ"#Q^(X/& M3S(*J;#J:IDWFKZR=$-SS(LY[-S60@$ZM_0 -MO4:** :+$[ RBIQ:A4^YL4 M7JY>40^\RG:UF:*6[4!<=-I$)HW7JTYLA\OEU$>IW/F1+[K M(GDAGW&.*W]@F2&YZPF<7:;UF9LV;4 8=1H$YVK6,7*Y&JRX\KIL#9^)X=>* M=3Q]KJG<+UYC6#37KZDE 2%B\]6QB@U'2NN-A\4:I^FG3990DL&=DJ9RRX/5 M8IN'EB0@'FR^ !X**5):;SQ[N1\Y>\\=J#5FP?(#:+1^=EMN<6*4! M\=+E#^!&A: R1BW[ZP^@[7X!]'(%2+BT%JEC=$"S&C>&+B1H(',&,2F)Y/68 M:Y:C>X:^9 3ECP1=5*_5:ZY<7^;C\RTI420G7)2C=1IC;L.H2^S\C2F@8>.] M*88R")AZ[<'O4*DCD KQ0,Z-8)DWS_$*(_."W%P1$@>D*6K:O$*)"Z8V!3Y@^\-;F"T6V[>5*0V48-" V+M+7X!"O=9H$8>'QJ]E^\+?O)A M=+G"'(N>%H]8',2;39[)'E68@Z^8=P8YOA4QH #:#8F.B(#P&V 3NCE11*(B M] ,J@U$CVN-Y6[9?G9#$GW9WY(%P.:?AGFSS3V)G3QUG'@-B79_5#2Z.?I+7 M&Q@$B&]U"YT"9JB9 5K*Y\RJ+-!O,A-4Y&)[3WMSTY7X)#:K3>+7$F=$;/DO M4$L#!!0 ( !$X)U5MJT(140< +U8 5 ;'!T>"TR,#(R,#DP,5]P M&ULS9S+D[L.I:5R=MK=C-V(J5T<2)74M)VFXR$ E)&(. M"H"6]/8%2%'1A0"/-SGVPI:E'Y?_.Q3(0P"\>+M.>?1$E6927#:ZK4XCHB*6 M"1/SR\;G"*F*D>A-](3QS[\@AXU1% YDN.374?E TW(]>M[JOXZC9 M!-3[A8I$JL\/HUV]"V.6NM]NKU:KEI!/9"75HV[%,H55.#;$9'I76V?=V?X4 MQ2\X$X]]]VM*-(TL+Z'[:\TN&Z[=;;.KLY94\W:OT^FV__YX.XX7-"5-)ARW MF#;*4JZ6JG+=\_/S=OYI*3U1KJ>*EVVCK:?>:&%HK/+!K<"6W>OUSGOY#7_>B RFZ4]+#5S1U4C:A^TNE14 M4V%RH[?VC8,B=&WLP423LB+7/JQ?AADGW1XHW:CICJHLM2W9EX5RVXVR(US& M!VUS1U\>&2V/Y)RQIG%K+I_:"666=:_[WROWLEF\S"G8?[_EC5U-M5$D-F5M MG$PIS]OX9C5'DO8/ZEE)9&)KK>[8H>*X7_NANU)Q)%5"E65>UD54?!"PTX-S MJV@OB;(5->,%X[M8SY1,?82V-*2GH_NP;!,_CNB5[4/B^C'D9%Z-]$@"9-K% M@%KI!I/J.ZICQ9:.30W< R60<0^5<84W!-3E]^B!SIGKL^N.._U2]V9XC/ 4 M <(_PQPU@FX1HW E1$;X UU*50/_4 ED_@J3>94W1-1_9409JO@&0OM$# 3^ M&A.XQR$B\XDB0C/'" +]5 VD_AOJ!8G'(R+V\8)R[E(\(D!'>Y4>B/YW3/1^ MGR\$_LV3.^_;TPV<_UX18 C^>"DA.'&+&(5[JIA,[*E> ?B?B('DSS')>QRB M,[\1"93X3@K.D?"!']E#Q#UD.B:\Z-70OJ?#R"OD4.PHN6FM373T_U"BP.#W MQ%#L*.EJC44$Z(-,J8,.!4<8OQJ*'251K3.)P/U&&&8V;K[@4Y9.O]]X/>1] MJH)R1DE.?:;0^)9W)H1Q4R$AQL=**&>4G#1D#HWUP'I2A(]$0M&^5RPE:C-F^AXQ[Z,SAZE)RUUB8V M^H%]>:2C>'LI B>"_W5 5EBY)Q M^DQA#,1N&;/V#@-['X-7RZ$,L\U_',\/FD4(1HZ2) M07L(N,>2LY@9)N8?[16D8H17LZ[204&C)(5^8PB4[Q5U$:?VTCQ?,^;V/*B[ MV\G.5'$[1\<;]*IY/ZM*I5"*&641#!@#0'T05^J$1]) MH'!1,L!*.XCCP\TZ7A QI_Z5$=5**&24C#!D#G4LGH/&XODSQV*4S-!G"I%O ML3[=?KONIIS-B7^'6[ >-\/)O6 58R]A?DV)+?;7*5Y7X;V135ZCQ0*'6<+ M9\@>!NXL888F1;>&3! 1V]1KM^?.D\G7EX(& 6>/)] TVA3!5\KY!R%78DR) MEH(F13H0FB7P%H%& G%.LL8N6AB^2)Y94BI?@*H\WP6/%(H=<2[28P]OO6>Q MJ'IW/BH>,Q*B[BL!A8\X*1DVB[@6SE#7;_9$WQ%#MKT,QBS\20HDC+L&MM(8&>IP2SJ\SS035P7'F2 @%C;C6MM(:&NB; ME*JY'>3>*[DRB^W^TQ!P3P$H>,05M4&K> %8?]_W7NS-"]*O4(.?J("(WFL2 M\Y$A<>P6:A1G>)$0Y2$?TD/9HV[\]!M%H']G%E3M7UOE'1K9_"ZTH**^%#02 M*&DMU#3>^7;OZ0/!T^V!#LH<,8&M,H:WCRN;9_ FMMH_!&PS!@T>1Z\T!G5+DE$!.Z-M>VLW^,3]_\#U!+ P04 " 1 M."=5''V\L0\5 #J

T]:U?BRK+? M7 O/K;U4G@0020$7' MF;/W0R3]J.KJ>G>E/?KO>*"2)V:87-<^Q:1$*D:8UM$5KO4^Q6RK&S^(_;>X MO774MZ ?]-7,3[&^90T+R>1H-$J,T@G=Z"6E?#Z?'&.?F-.I, [M)Z=24O+; MY46STV<#&N>::5&MPZ:#5*X]1,^/K=.N;4/E@:[XQ .23BY,#:W*;("_\W[2 M:0QTM4*[9IVNEM>5FWI&EG++\'!Z3 >,H_I*B#.LD'T[;ES,NEOA_6==DY9! M-;.K&P-JP1[B3-EX2H[+^[Y)XB;K!":"[XF>_K1RGH-X6O+F6=BLQX70W6C9QX/PFM7D?;C/9&3I&M(0,ZNBV9AF3!@RMSJT9DR@,@I?$QU] M@#WE5#XEQ82X,:K )\%_CBQNJ:QXE'0^H77 +$IPACA[M/G3IUA9URRF6?'6 M9 CT[SC?/L4L-K:2CE0F<5S2G?;H_^)Q'S=T>F3.USHW6R!=]X"GS%+1IZ.>LGP;/6. M ;2??";WH3&**9\^9IX*X MU-VYT@LH14[>UI4),:V)RC[%NL!\!2*EAA9I\0%TN6(CTM '5-MS'NP! @;O M"C97^),W3N'F4*63 M%TC8E&/BX@OS(#!4%\XXK"-"$6^!4Z7MD#F*OC.3'T ?)*/)4'P;/TV>\QHL&J 13CA5!NB!5G['"4#(#8#-0 K\2*@EE" M 24#RT6XH 69 ::9F4X/5+<%4]A10( (XUCH"TV*@A?WQ"4Q-I68VVR!>O@4 M,_E@J#)');B@@I,[X$S=-CQHT$WL?<%=,N'*TB5[JLL;Q@2UIT^GS[F"+5W. M#"*6PD*-5+EV'MR9^<$S<,E0>"ZT(=!75Q:Q $_!L"K48L79$KR99FT+PV K M(P9Y+?-H!1#P'KHD#=+9UKA#9!"[!6H.M@Q5=^2Q 'V\RKRD( F>+F-\1 M]D@0+A%$IQ?#F"F5!3B@ & ;%VF+8X5 4$LW?,W/I\$\CF&S^H!6F*8/N+8* M[&JZS,,-F]AK#U!A@:"NA/KDT5$/GFX\2L)X^,1_CX:>/AU0H\>U DG%BO_Y ME[2?.CQ*#D4GOREHV"J+UVE/6"R_-AYQQ>JC&D_]%0LTM'4#H,8M?5@@QRKM M/! 9-+VIJUPY)&YC6["U2[-VM UQD_\$RP-/9X@A_NY/'W+)(';#H(4Y M6&5@#LF4!-!UD0QS\\DK+=;U5K5"FJU2 MJ]H\2K:+;P^R62W?-&JM6K5)2E<54OU6/BM=G59)^?KRLM9LUJZOEN$A93:% MQRTU^Q Y6CJ,KR3*"5AB-I-?!ONYVQ@.^@4<[LP:5UD7L*"VI7N X@;O]:?/ M7$&0LROEX(/P^5H$>C-&/+EN7)(C= MJ6,_<_%_]EGOIO_MX?1S[0"F>ZVWY8<7*Q[$S^==K:,D8EK\AS\_.']N3D&! MFFQ4KUJD4:U?-UKOHQ3KMF':5+.(I-\9!<>* MF19A3]#3;6;*;@%CV.*\VLK.J:VZ\-ZKCF\?KK^:XZO617V_=##*OEA_.2FX M3S$^M@H*0!K N+Y")Q/ GFEA^BV 6*S89$,8U8:82MHC./,_:N_W5'N;,\OS MK)US6=O)@C18CYN8_K4P*Q3.V=U63:.7]6_FX_T&+',8W%CQ@M$A:?4A/!LR MV^(=6&5-ZR1>P+X;TB,[U3$%Y8AX.^K$PY=0DYA#UL'L@T(XD-8R":A3T";& M[C\R]9%DRJ)ME4&CJ@+7=,2Q5BHFO@^IHGC?G\T]O@!Y&O=V=%6E0Q-(X?WF MY#N.+,,#\,0,8&RJ>D@#4;V97BZ5P^G_KMZ9H)T+5%QS4WA=P1'+6,R#\>V[S5 MRS1O?O0W1N0(!&)%.1?/9"0YFULXA8@@.?PPWDS5K"+TCI!$C&=T"#$,<@\1 MAJEP$>@*V9RX+'JAJ;P!XBN+8,Q*T)F]Q;R8I45:Y/#US88#\]_2I&TL/E@]&@U;^_/U$W3 M8@8Z5BS30=O@2B_*M5CDES M\&/%R](Z._MJ:[VH A9&/X=3,F&TK>O@/JH_^##:9VV>E-6G+\WCL_KF;'@8 M='"99"FSAM"L;;LC]>XFS+>[!#320P/X@@^I2MB8=2 &?\+ %XP=,\--]B;Q M .H1)-]N.'6FAO6M3P+7L:=AS.[&U").%C1P'WC'H6*5LYS'?_YU($NY0Q/F M4MFPKVML>TL3?LL>.DNJC=:>0#A#@3D5(!-(PDZ4TD1E58*NTC Y'5<^S+?V[XX&>FL6Q_7VQM ?1YF MK)B3,O%4>G]Y?//*G,X*MOB%' EL=94LO3:;]F+P.R>Z >1VDVR&2 K 5^HH MI;WM+=XESD$%*!NT6D2EII>[?TVNS8\QIL9>ME/KY]\@: 6D?E&J[9?2:+/) M6<0#/+(^ ^K@D18=#@T=#!?&H&U]3-I,U4>$.^==R%SD('Y."#=!JUI,4YBR MO67IP$L#6[6HQG3;5"?$A'#.[$[$H"Y74?7J;0#H1'GNZ9DO 0R."G*I-O': MNA!#Z2,'0 M=O$G<><$//V3DJ'O0!>EC&3D[/:6PQ%SAZQXMKHCY4CYI$'D="H!/7<3?QI7 M>+%.$_14!]:M]2Y!&$$BU7"6X#GK>_WD2REC]]Z4)1;Q>1T_.#]GLP+QG&D7 M.4+*T+@D^YDB<-P^98E,*N%T_?.X(N]R1=U@*)1872R*<5 %&]?=;I2WQ^TV MOY2[Y5'UY:F;=;@C&J]-< G,'N_XIE^B0[:W7)91XO).>Y>LQ3-.WS^/:TKA M7%,S39L9*WG'.-AGI<&H].5I_SUY9P&[5]J==9E'.#(.\Z19/+/368]YW+YO MQSP;8B"?'74\+V9 $# ,*Z<2@N-Z8K#>PG)F?K5P?.PL??A)CS-?2%SA':EE M :B+OE<8D$UDT,?WGCH5!.[#Q0.WI>F=%KZ\YA1A=?JD T&C/RFZ[WRBV3$1O,/.T#TCGJ M\T[?.Q^82?)F#C!?21JWW5GW0NO;$2O*6W)UWD22VT)B(I)Y&;-[.;XX^3[8 M1#76/$R(KL'>P,8U+;WSL ?K-<@356U&_IU*I%+1B>W5[/W2;7J_C=AW-\*5 M7D=X(VI@KE*-CO*0ZSYV-K + 8"QXD6]]>V/)O0\QWO^2G0-HD+9P7&'#<^L MC537BIHCU%.+Y49A.*&",Q7Z2$Y5O0TQWR4U'B(/>W^#(XR5*;::IJ#'R4A[ M0CHBW09#'D";,U'F$4R(;6]QD\#^@K^*T_9(S]!'5A\]UR%FR:A)%-;EFE,N MZ61-4EFR6)8^JT9/DQU<9>Y0)$Z\SEP46@ZQT!+3Q8[W*[?CLCO7]M:*&O?I MK.@*SP;ZYOW ,54U@KS/B+6>&9 %:]$\^*<"?-F!'BZM-:JF:4KZH50W&8I9 MALT63V%#T1+DEU,K@K#IQP?=\U#)["X1-3P]G!/<[2TAN7PAB]T'L60J!%$@ MEIHN0BK;9*(7 !7)$BS'+>7\9M$<#4"4(?<8"-/*C!>J#%8$_PMO95&HH9A.FER)"NC2.W0:T/FE.$'\)XK/Y&4YR,OC MUG1ISBL4X8S\N?95;U5Y[9&^O-YFG:1"%%;K)1/>C(&?46$>?2H4B&V?<>85 MZJ[XWCC>9/GY"]1Q-*D0R"&,>K0QB0.3.Z=PPEE;7'RD.^8GK"2'4'9?N%:+ MA8;!8SCO%?$%\ :C#_$V _8$'(<"9S_(_1"(B,9S0?KW8-F1Y.NW8):9\6=B MYC,U+P3J,OAJ]EX:Q 8U^KUM6KP[$3>>+)1,IQ*Y+-?"3$"T_ENQDK ZZ9K% M!DM!#7HNZ),,\)%75M1K^KH>D-!SJ7+-$ A5:%L>AG\ T$Z]DF)"28:"-P=YF M6'=W-2+D$AY]>*7OIOAXP^GWR/*Z:XCRO?<%'13WP!]H<'R32B'-3I^KY@,X M-)>)2F)["WP52LJ8.'2G)(J+D^]S Q,1*CEQ 46D#FQPLS^/CN.F\.PK@PH A]^KC?< TOAI*$+!02S M1DBS19)"#Z?\002#X!F:Z"#Z7#F1]0L9.,)]G&Z!V%1O'_?$K M#1&R)VT^D @1UOL)ZM.H4>S?AY M"/]XI7K;6QU/93@P514HA$Z@B3E-@"#0<$@"GEJ<.2\/,#(0 A;DKSV71!Q# M8[-C\+83'/M6,:T1K&#LS$4]9MW0QT 24.M]\%)U8P/!)+?+8G/MGZ8Z1@4>_M!_2> MQT8_K&% MFBJSM[TU555DA:825^&AK+A^UX*#AL)E\]K5:41OAH7!!G^$5>0R MAXY[Q4BU>7D-B]!ZB';"]0<_O)U9LJVOU>[R\[2[7W6B:P<:>(6&7U#PH-TU M\L*/M:KV%]Y1AZER&=J.S_3V>OIZY-I.G?J>9J" 5WV]>GEWT(K M1ZUS1]E=7MD7]7..#F_/A1^Q].A9+PBO6;:2_TMLC$M?]XURY]T=GRLP!\\[ ML9YF+5&8O$6NN(A@%5Y+WG3,I_YR\U<8T W%*_ !L7C#E_0I<:[_M0:R+&>E M=%:1[M@XGX]+B;XUV&3*$$.0J86FSWF+?S%7N KK>L"P*,* A$=N9&<:;OE2 M?[M3#'\9_>4WH+_\YO3?.-9K[&3&VTGA%+I>Z=R-$>^TFQM;MI3*//^VBS5J M:UZ*3UE'%Q!/8;S,+"P8LVA/S/']Q0T:.[@KBN(FDERGKR;^6@3!/Q=!%/?R MN=W$BEJ7U[]/Z)KG7_(JY?-@KW,2*!^2:V$8S *BX)YX'Y*O6&$'S>]S4/@. M;W;&2?"O#C@$."1X'6N!E S:YAWO#Q$@D:YT7+H<."ST1F$+B?]I1YF_DLG7 MO%BZ=GI5:MTTEE]D_='\>>=55?&$:WA?#\8_(OSQW\7JU,(\VMQPHAEQU+C& M):E[854TB@V1;H?:6/DBXE3W[E$GF#4!+6C0G8L"VZQ/U:Z76'=.7)P.&+_; M&KX2).:CMM77#=#=RKN$M1\QH @WX:'!6Z@]!4!HG3[%Y-C2P1L]_;ZHENJD M=59ME.K5FU:MW/0.0:_*B==?W;5RH?X.+W>30I73\@M=7DHRO+=6F(B ,YCS M;J]=4NV\%,F-XG@,8]8IO%XK:IQ'-8.X)LTDJ>AV3\6<8()<:R;?)(=LD!:. MS0[W:C?(%?.TV+C0;!!9\>)$X:U)4NYSU@6CY-W-XQ:GB#P<1DOB3^(\L_;\ M)4>L']8/V"ANZWCS:9\W?X$7DWR8,K_WJ[G;'*7Q1 __F)@XVL,_7%=<\T^7 M'1S?B8)E<>V&[T^>L<_CDWNE>CZZ+UTVVOE>Z/& MMXQ]<6--Z,.W'ZWZP2!IG>[7:HURDZ7^MJL7)]]3!\;-Y.R8J:6;CGFK&KG& MR?E3^?S^Z?9XE/UL6<>#TUM6J5^;N1]_WY[E>RW]['ATWFS97W+ID?+0[DLW MIYW['U]-><"_G.NF^JWRG3-N9.7FT_#APKBGV6-YI%^WRJEV_O.PF\FP^^[P M7,W>WSQH/\I*[8=]/##[C>[#)?_ZY7-N_^FV\O?U?N_\K-88WUR=?#?3-Y;R M]_>?FOKX_42]K^8N.KR>R?W=J[#'FP?JD./_ 5!+ P04 " 1."=5#S#Y M+CD- ^*P %@ '1M,C(R-3$S-60Q7V5X.3DM,2YH=&W=6EESVT82?F<5 M_\.L'QRYBJ1(^4AT1!6*E&W%NB+1R69?MH; $!P3P, 80!3SZ_?KG@$(2K*3 M;*U<6_*#*8$S?1]?-W3P?G)V>MAN';P_'H[Q*>C?P>1D+#M/O'MMO_Z MX.AB_+NXGOQ^>OSCLYE)BSTQZ&>%F.A$67&NEN+*)#+MN <=<:UR/7N&B[AZ M6=U+9![I=$_TGQT>'!T^3Z/; MN9[J0NSN]@8/D_BK0E:4NX7)0+W^=6J*PB3-)[&:%?P[2Z?34*6-W[VTGTI; MZ-F*A3PX.7LGKJ]&T"?9V=EY/7CY.AS\6]WN[G9W=!+U^X/>IRQZ)H:GDQ^? M/?NJ0?ZN-I +1[\BVZ,S"V =E3.O4R4S,9FK7&:J+'1@Q3!-39D&(#W,,J/3 M(L%I86;B2@=SF8?MUFE/7 =S'=O%JB/.QJ(P0A=6'!E\2P?'.E=!87(KOH7! M*FL]NEM&,IGF.HP4E!Z*YVDH[7P?-+)")5.5BS<=L=/?V2&=D;/5]_<,W!$G M:= 36^?2AO+SWNGEY)\O.D**J3:%"N:IB4VT$H%),IFNQ,P$I54P:RI"=:-B MD^DT$@4D5@4>RS04.DG*U'1-&KBK19-9NU684*YPT'DUI*^%?-"SXHYC.^+M M\'IT01^C2_Q_/9I\V=<=H68S_*AO5,,F V>37KLUSM?$!>R81E:8&QQYU1=MNS4P.BR]UJ$0NTT@1[T"";6Y[3R->G\?AY]+L_P;C MY4K,36IR\KT12Q4CMI1H^@-1LIR;RBLPC))Q,;_C$#)DJ%0F%JE9Q@IY0.2F M)K:H)1SFSW-+/.U])]@BEX6*5IWG.8LEK-2A&,US;5':$:_B3.=RJN)80Y;+ M.4)O-)?2"JOR&URBT$/NM5LRP(U$!RZ(C($M) =XE)LR\P3M7&-7KZD6!!3 (QGZ&I3#JBPG"*PETR4G79M0&I1O: FV1"'&1X0[G'-S.=J;@J[R%^ MI&Z0*)F"^:R,?9:B@7'B:\7!6MM+(@6]"$N3Q^'3BN"-;HFB1FK"40DL-)IK M-1-GU!L16QL1$8\OE5!R07J5SP4EP@.'?H>3Q2&N$_!*:X-7%.LZ/FH M*AT7%7[8HJ9/D(1S!4D1Q;0MQ]3\K3UWT.=0$:FP]E9Y=%,(NH++E6#W1]>K67QG9[*\\/E M5Z=!7(8):BG9*CMVF*>PEA1PE:@ZLRCEX[S3064*E\\: 4QL?-ZTALC8:G[XX8>Z:2 MK ?-FTWN'N+R;6^&O .O*2--<5Y=];Q.4!%U4<+D6^>CDQ<<&E3T$.4JM41W MC2E08DR^()]RJ<%8-WX6-M M^BK%]S8,0I3KZG]=UZ=VR_=E9*F_VKA0APR1FP PVKA2>NVHJIV[6/T2_S^' M ^W6UL5X.'I1W8"&O4U?-Y"*!QJ(-$06M9HIZ<9-@%/$ YU/0 J0%LK5Z2$. M3@[IZL_NJP!1M"<*CKN=7 SR@9T%,IBD$*L1Q+540<=$:U2 MY8M-QP\PL:$>).-ZUFVWV(IN9UI/0[A"- Z$:#-$U,63F- MH=9,QSSMLD(D_O7QB)$Z! %+>2,UU(X5+DIQ/'XWO"+\:\R\1]QDD@\&J30(6I 8=N:"AJW#[%1^0J[!7E1;(6 M8_=U1RP!I&A2NC'Q#55ZNW ; %HIYV0&(M*CBFS5A@$D3]@F2ZN[/US;::IJKVZF!F<_3+#=-A>8BUZUOD7U[%43O'R%*4^:80'9&A MRS@M:AH],8R+N2FCN>LP4Q5K17"75S@,>)MZY&H6XS?7CFF%Q)OE9C"(ABFH MK:#P6( !ZBO25DXD ($H#-%0_^2Z+:>?O,UH"YMZ'[B?V2OHHQL^:1I!NI"3POW9B'H=LU<#V;T3(&S G< _8SP*;VV30 P#OMS>IPN,O; M.Q]>0\LF^5-3B%ACT.&%W-[:K-7>DD9M)%98!D4%6I(L5AR7M*/?7.1WA$V)D":RH G&G8!BA*YA@(P M0K20BN26U"KROP_V'(&;EI0'@$6#IJQ>#J-R0CS:SEE[^<#5Q6.Z.LQSE.D#67S=I@&Z (ML<5!VT MM L?MYM$V7L457-YHWB!6[V$(L!/ZUCR702P2F7![XFH@KE8WV=EY!18$ ,C M M],638>X2F*G0OK';K,(."-FV3I)K_HJ&Q1#P->58L!P%DBRLT2%6^]$?:) M[YSO//!5DK#?03ERR4E-BMR0K5$S%"9G=;H$FO3]8N/^=H)V1";\ W)OQXB>V M89J6O*!QKTI2FB:2=FO0[WZH)Y:9MA1*]"9$<(N$BH';W+QT;RX'W$!GK/7& MI ""9[SX&?A7G*YIU>6DS$+IJX47Z)=2YM W1J5R0ME**J"4[B]U<_8F]T?8 M$L3?^AT'O9>@EDF?38G0NOAU\1?Z1P57V+ZTI=5K)(/>)Q%7,[H76,E'9UL7&?C\5%^7PDURI1F[D!G[ I'_LGM>T87YY/A:++W MY##W&#@L1CP>]\1%:O5CLUN_W'@.N+#O-_[K5RK^3A1]/ P!;O1/Z[T(K46>QE;D3!8H1$MTDM]-F4:/S>[$+YG0 MZ-Q+"?O8'(=Y!+QUB68&4/7HW'8&.]TW_3[ =G_G&\0E1>1/DC3,O(+_\^C\ MPIKF*TNTG7UQD;%O]\2IM,7_ST[MT19U=6U<;N;)^]UK^#SHY*VQ8QS:VN60"#&N;2Q(F!-C8V;/GO)S5 M[I9M3;I;/7TQ>'[]^:HDM=L& M'/>.\+>@/WN#D\'I\?[>NOD;WZ[;K_<.SH]^$?W!+Z?'/SX;Z3C?$9UVDHN! MBF0FSN25N-21%S?,!PW1EZD:/<.+>/7"O1=YZ5C%.Z+];'\E'F;)[M[ZQ=(C MN;S.FUZHQG@L5>-)OBLJ;^T=[!]?3]10Y>+ERU9W;_U@_^80Y?.[XL9H=T]L MWFKF.N$W[:_\4O6#H8AE1M]O=ZFQL!9W_D]B=#GY\]BE2[EH >.!>O&WUGRN;"E_QZ-)4OQ99KD:S MAYG,EW$N4Y[K5'J)&$QDZB6RR)6?B5R+BU1F>(3'/O)R3XQ2'8DCE0U4_+I0 MV:1>Z^=%,!-Z)([>GC7;'7$1%AD(R$(9JM^+R!N*AZ'?BP/Q<^_MR1G4X%:2 M)#V]=7IAW\M%/I'BN/_N M7!SJ> S.9 ^A!G=IZI_+OY/]=S)07@R):UZ:TG'S52JEZ!?I5$V]D/C9Z;0V M1(2))UF]IF(Q4FF6-T,52S'V,C#7%[X7^S(5B9'N3AJGG9$5@S'J2X2B.CDWI7OI!320\QE!75N>5'*1V4BUCD& MR8M4&G[K.)S5:YN;STEXI4@"6(*7029>1I\38P.R;;_('Q^WCN-4AV%$( :C MU:175IFR)90@K:S7YC!!Y'T<*@XJ:.&PXL#AA<#DJU#]W[55\C6:.).^CH.F MT"EH4&E@C$?+3"<3;ZRM%=5K2V;4$)Z?JZG*9T[7FQ.XI+E,,6JFLIR6R9)/ M4H4I:(D*/#0?R6B8.F*8@(H%WJ,P'@;)JF[ST,-*53"6#?&N)U;BP,LFNQ@C MR<$"<'6S(;KM+H#]MG-Z,?C/&@0AADKGTI_$ M.M3C&3@?)5X\$R/M%V14.H:!366H$]*U'!1+PC^&J2@J8MW4L6]>S:N3U6NY M#KP9'HQU >$'K*2'=O0K!5,?2LB5'3(-S3:[",*E.K# O6#J\4"L54[')*#" M"V2L?2_U50PVB]77Q[TUX]HQ9[U6\>_&2FC5%Q-@AN@")C"5\C$*-!4_);"G M\)@BXN _,JP@5\TCY7_XH)-1LR-625_7^..AIL&,P36(>'!OJ&*&B\6AFZ:7A3,C1"*/Z,R./)3F! M^8ZM+C@I&1H5(03/2.68"P!'W(NQ=02<"6YRV'"N7DN^)*+Y.$PM8E0#A@>. MKJ39;X7>G7/]M,IVR,UI6KVVJ&K+2'9#UBA;L9-68Z?7KIH">3; MO2HT:I *80%3(4;T,9);%, ;9'#='+,I@<+0^1 MY A6!<.#4;[QTBG1Z&RP[T^T#EL$OX:+ %X7ND0FP$DJD>B((M'L]DC4(#"> M%"-OJE-O&,[,LE*VCQMA).(DNWS!(6*+0+]>TT6.@609:WIC,_M45OPM\9N^ M# DNP&__0X*0(F^JF'?&Y'(E''%.;['5-$-])58/+_I8)_;36VOSR%2 9HK8 M0+ T> )<*E(/>C<&8WJ9F0DB*>F5',Q(#G@-^O3@Z$,"+L!I-4(N>>54BR;S MPDP3J$']_ ^TO+VO&+KDN%4]U.&4W35I1X;^SN(H= MMJSN/RKL.F8E91(^5"T>*I2'7/8'NG ;O;8K"'[!3RL MNJ\%W'1(:-!V/!-WXQZEGN';=UZ: 3/%&YTE*O?"EL.WGV'*6G^@0.2*5!RJ;QT#,TE;VUXT*!: M8R(L"5$+TQ A_/1BE46T@2/90'N+6/U6R 4G8&#S%IY@EYTE$I8:AC.#=SJK M1H_\*XL#5G&=<'#$^!=29)L9E_2V\U F\=!IM[=R!@V(*0F151WZM\OZ#7H' MI\?B\/CT]*)W= 3;_/%9^QG_WK_H';K?+4%7*L@G1%'[^:[X4NIL%C;);Z9= M.9@<7+IIX"IRTD:W!+Q(WQ\MD=%N=;=4_(P2VT=CH.5<$)P-=A1%BZE"FG&:ZPV-P_%^:.[8[E9VU@0+8/0?VP+B1"N7R MAAHA=RJG2F/N5"8ZS3-#Z?K@DGZ0>/ZNDK*)J'KMCKBM6<8BJQ>O^FO+T9O) M]V7S,*UT1Y!E$6O%U\B+ MF ]A&>Y#(HL9)>(N]KEM)Q[W)3S=$P<=!_'>,@?OB/:9G9W6=H6=YDEF-C^Z M]WY_99QC]/?[>.,Q,OFK8,6DN;$O6][1K)X#1.Y(=HLOR'6+U9\*^(B-MLD& MKI6>P.)8@+V V8"#BC)9W-EJO7#").%^]O[L#L%^XA"TY/V7GIY67BQ?^:]F M$W&-#(,=<8%='*5$$3+")4(_1+-I3Z+WCD[^?=O8G>XM.K%-GPUU&@!TW6<' M(6TO.U"X#(%Y )N'J\F"\?!>^N8\Y;IA_#?'YI#">\-&A.FN4K2]BT4$9E? M.F6%,>O$&<.,/R*=OY^]O@&@F7"-#(=R&LYRX<\31%-2<-9K]?SRJF3A MCM'1E^WG]1J$(%9?$K^>^%3E$W3+LFEKV[&)M&M7;#XQJ\*LTA+K-9L@@*?< M$2]>DC5VOBFKOH8+G:_#/"*L7EO=7M]>$Z0JU4BZ40D)73CRI#X+ZC-AEU'5 MG^T7SYV];?Q=E.C%%NG0QOKFW3JT<-;_J4#RKYB.7DZZV03T]YYP^_GD:/#F MQV>D6L^^EKH_:))$ZU=&<#>/C4=>I,+9SJ=,8V58A.&N/4!>GN16)MN$?9%0 MIGN[W8[&0F(Y,]$55U*:D[D;5P$6,ON4Z^.<''8:B!@I6_>'P.&[%=UGX>D# MBFYCZ="$#R5U/);8]^88VQPHNCPKG;DBA#>GI$;0 1TF\,'!XQ38]V9K/2>7 MT3S5H4#B*.])(XRBV&N8_&E#7/38-G:FK"V)R$]B)#*S.O$"^B. MXF5YJ4#,MQ4DFQ\ZS^W]@D2F="V(LGR9KR'8U<%%_X]M-)[D];EAH,KXFA'= M?("CX83@CMAJ\Z;OXK(A-D7_J"&VL.UYI!+YWH*%8P1F[&6&D N?F2\;#YG' MPAE5M_U\#1R9T357S]WVLP4>Y04KAY:/4XK?FUUMWE(2L",.*$2GE$)WJS2P M#AL8_LT_SXZ?S.Q!!#1(O3@SE]CH5BU^S#)I#A!A0K T4Z R,.M,ATL,8)'SW,9#J5 M@:GTB#5=XXKH_J-WK:(BJMS[XB3#ZKO!D7D16R=_(H,G23Z0),L$4#.5H1$( M/IA @C[?)I]+D 6%#PJ?P+#<6_U6J/1.>?W54]M<67:A,ZKT.9*YI\)LYR]? M.EQ=X$#EH>0EN:O9).V%(O#_$8>5F\GU&HSTU?RBYFKG=$VB55S>7ZQ!ZMY2R[2Q4X0SHKO\#,(&7(WI%/M&IX84MD/FI5:F1L84P M]=IB)W ?TAW8;7Z3X;:?=AK,8/ !Y5CAG!=%AR.MT.QN/ M##=X7=6Z2E=1B7B8*D=L<157^]LK>KQ)+8NN/EY1NG",='<-R&=5+NZ82LUZ M[>3$*^\IVWN%]LPR_Q9PPRQ<+%JY49-2KYV]Z8M7NH!^,W<&*8;[%L##U'Y; MX#$T/ '/EP#/UKT#ST,7^O3*:L%JP- WAUZ/)3X;W%J5O+KW?O_L<-#>W-C> M^*'=H6KVFLFJE_W*'C$_6ZU,MZ6UU^N9^=LI_$\>7*Y4K)3LZK==LDPQ3 MPC,/ A>!&ZB<2+YHVA A<)I*V1R8-\3K]=?'/RU!.!?ZVD6IS!;ZTTR%;\_9 M\BN-6=+<=+L[+\]U(FQ3 $7H W;S7V/BU1[3,R$A<81/0$ M&(EI)+,M"669)NUN59?\YOBRV[04&P"JUSY>BR<5L>6VDKS*C=DUXCC=/KOU M";I$VS)T'C@/9E@#HNNU.<%ROK!% 52E-$\_5I=AQS]<'-^U2/ 6*G/-B4!8 M-CV@NL;/5+L;;2!<13A767[TR9;I^J$RIP>N&)@Y4$YI"/5=<(/<34 -73(J'@\E3(JN['8+A:/I._!Y]03=)_J"3Y:3_"7E'O582ZT M6GMW::.H3- MW'2-P+++VJ) TW]J6C-?.812&H68.#;-K^1MCZW M87.^0Q6JW'8 JNX7EYJG<-\"IF >Q?"AR]*>T'1FA7-]7^AR(_$DP1?$D\YFD_H\^3,_E%2VGZNRZA^\E=3,*T70 M 2_(5OL>3W,.B/'L=PM6,5&["G:HR(Q0#H+5Z"=AL-&(&[,74/$%F14/&MZ1S!G8/NW<=]FSW"C>9@CZ4# M:#G9S?Z?KO&9X,YGI'7S'F?UVM0P@FD/K6^4^QEF!78/!H\7H=BDST!#C M62Q]@Z2V\1A^H2KSLAD.]$A%(, $ /$4XEF+7A84.< MYD&+C9[6P3UGN4>.);.R#>ME0(=5#D&Y5>9/7N+%:PW1*VBB4'FV10YIQ/]* M+\2_6^(5(;SFMCI\CF:BUMO5NR&F*E.YF.1YLK.^?G5UU0KQ3'[= KH2!DT5 MAJ;R>[L3&JF0;^Z7=X3[QX?XV\M!"+4>FGHJ9)\Q!>7'1Z][EW1]#LZU,@-V M%*VQGO(M$Y["$+Q\0"V015*UNG9QQ)6'^R_.K_\N7<)CW-^;J*K06]P M_.[X;-!_=' SX#YNF05%XGA$'V,-6T/:/>/CGO?:G>;<80F]9"XF]4<.6][3#:J*8):+_N M$+W\/M'42X5BAA+?J%0@R2N#V8VTO):(JS+@8:1",GF"1@IQ4XI4J$>+-S.\ MX+"C1$\BD&,X-UZ5-Z @I,9DW*R42"U7RP[65P5GQ9N-J @'K=!2#Y$Z]GQ?!7*\H/L;[B M'$.]5L3F%U::QJ+&5)G@^8269BV^+D*X+*^@Y(2?%Y7.<.1@U&B$-VB?D9JF M4,Q9@ORM MW<5^;5BK]9PZA=?G/8Z5+4"HH/46O.OPO2CQH*=952=<+UQ[/[ODZ-FYR6"@% /R=]C%P6G1ZB0<@Q,.ZL) MV"#<]0>598C\=VGC8!K\V3>Y/XTQ1$J?8;_H,P/X> O/<^=!NC-A]S,L D!F MQ/G'5(ZA+;1$$@OV)-0VUBI["L6EW088ZID(WMZJB,JN.3$WVB'[LQ%\/#8S MVMZ')(O,"L)8O2,!%D,R6@03T^X-/#78L"0L,W*I(/.OJV-@7!\N8!E^2,&L MWBX.RM(CK9IX4\E9.):9FDH*2 TVI6(,.# =-K7MQ6AU?9<78S>/I/AZR+01 M^1%IL1'AF/K-0<>$1_MOVW&2W@S28ESRH@Q6[5*IYZKAQ#C55[2A+2'/&KX1 MOI' 1X=;HM+M)"VYINW>G&+3TSJ7(6$3+)MZ59%QF&Y6N?5QGYQT;BILWRU[ M587!;AXOSE5P 5](+E5T(:S\"+RH$BP82F^$G_^@:_I*!W<$EE5]L7ZP%\<% M=^?C_2@(1;0;U6N==O-MZ7%&V$KC&1 M+ 9\1UW_1,<\V+5W-QV<%$G@6;2P!/VK\%*LEQJP&Z(R1Q5BJ.:_RM#!LMP^ MPIR@^5TW1JHMX2QV)!T%<)B\(,_^CR$8?G9X/> MX>!!+I ]Z-J.$(>%T,?CECB/,W7?T]%_;:("TM85A N[XG"BY @Q/R)X=AGG ME%6\_[L =W2=O^]IMSLOFB\ZF\WVQG;[WK7H_7Y E=O_G._;:=O^.';M[[P< M0'0%3_*++NB>_OU.=V*3('!TIIP@N^\9>^D8\18=2""HNO?9NIUN<[O=1K#= M[CZ 7I)&_M.C%29V@7^Z=O[IBOAY![ ;N^*"TR,#(R,#DP,5]P&UL4$L! A0#% @ $3@G M51Q]O+$/%0 ZG, !( ( !&Q8 '1M,C(R-3$S-60Q7SAK M+FAT;5!+ 0(4 Q0 ( !$X)U4/,/DN.0T #XK 6 " M 5HK !T;3(R,C4Q,S5D,5]E>#DY+3$N:'1M4$L! A0#% @ $3@G57[X MM< L%@ =VT !8 ( !QS@ '1M,C(R-3$S-60Q7V5X.3DM ;,BYH=&U02P4& 8 !@"- 0 )T\ end